Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease

Brady, 1967, Enzymatic defect in Fabry's disease: ceramide trihexosidase deficiency, N. Eng. J. Med., 276, 1163, 10.1056/NEJM196705252762101 Desnick, 2001, a-Galactosidase a deficiency: fabry disease, 3733 Nance, 2006, Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome, Arch. Neurol., 63, 453, 10.1001/archneur.63.3.453 Smid, 2015, Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease, J. Med. Genet., 52, 262, 10.1136/jmedgenet-2014-102872 Wraith, 2008, Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease, J. Pediatr., 152, 563, 10.1016/j.jpeds.2007.09.007 Germain, 2015, Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease, J. Med. Genet., 52, 353, 10.1136/jmedgenet-2014-102797 Oder, 2016, Long term treatment with enzyme replacement therapy in patients with Fabry disease, Nephron, 134, 30, 10.1159/000448968 Guérard, 2017, Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement, Clin. Pharmacol. Ther. Cheng, 2017, Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease, Eur. J. Med. Chem., 126, 1, 10.1016/j.ejmech.2016.10.004 Huang, 2017, Lentivector iterations and pre-clinical scale-up/toxicity testing: targeting mobilized CD34+ cells for correction of Fabry disease, Mol. Ther. Meth. Clin. Dev., 5, 241, 10.1016/j.omtm.2017.05.003 Nakai, 2007, Multiple leg ulcers in a patient with Fabry disease, JEADV, 22, 363 Hossain, 2014, Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form, Gene, 534, 144, 10.1016/j.gene.2013.11.003 Hossain, 2017, The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome, Mol. Genet. Metab., 120, 173, 10.1016/j.ymgme.2017.01.002 Linthorst, 2004, Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta, Kidney Int., 66, 1589, 10.1111/j.1523-1755.2004.00924.x Tanaka, 2010, Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha, J. Inherit. Metab. Dis., 33, S249, 10.1007/s10545-010-9136-0 Sakuraba, 2006, Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice, J, Hum. Genet., 51, 180, 10.1007/s10038-005-0342-9 Benichou, 2009, A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease, Mol. Genet. Metab., 96, 4, 10.1016/j.ymgme.2008.10.004 Kishnani, 2016, Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction, Mol. Genet. Metab., 117, 66, 10.1016/j.ymgme.2015.11.001 Eng, 2001, A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrateclearance, and safety studies, Am. J. Hum. Genet., 68, 711, 10.1086/318809 Lenders, 2017, Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease, J. Intern. Med., 282, 241, 10.1111/joim.12647